EUVIMEDEUVIMED entdecken
Open Access

Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy

Yun Liu iD, Chen Xu iD, Li Zhang iD, Guiqin Xu, Zhaojuan Yang iD, Lvzhu Xiang, Kun Jiao iD, Zehong Chen, Xiaoren Zhang, Yongzhong Liu iD

Science Advances · 13.09.2024 · 10 (37)

DOI: 10.1126/sciadv.adi7764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 13.09.2024. Verfasst von Yun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shan…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Syndecan-1. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor cell–originated events prevent efficient antitumor immune response and limit the application of anti-PD1 checkpoint immunotherapy. We show that syndecan-1 (SDC1) has a critical role in the regulation of T cell–mediated control of tumor growth. SDC1 inhibition increases the permeation of CD8 + T cells into tumors and triggers CD8 + T cell–mediated control of tumor growth, accompanied by increased proportions of progenitor-exhausted and effector-like CD8 + T cells. SDC1 deficiency alters multiple signaling events in tumor cells, including enhanced IFN-γ–STAT1 signaling, and augments antigen presentation and sensitivity to T cell–mediated cytotoxicity. Combinatory inhibition of SDC1 markedly potentiates the therapeutic effects of anti-PD1 in inhibiting tumor growth. Consistently, the findings are supported by the data from human tumors showing that SDC1 expression negatively correlates with T cell presence in tumor tissues and the response to immune checkpoint blockade therapy. Our findings suggest that SDC1 inhibits antitumor immunity, and that targeting SDC1 may promote anti-PD1 response for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorSyndecan-1AnimalsHumansMiceCell Line, TumorImmunotherapyMice, Inbred C57BLNeoplasmsSignal Transduction

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorSyndecan-1

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.
  • Affiliated Cancer Hospital and Institute, Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Yun Liu, Chen Xu, Li Zhang, Zhaojuan Yang, Kun Jiao, Yongzhong Liu

Zitieren

APA

Liu, Y., Xu, C., Zhang, L., Xu, G., Yang, Z., Xiang, L., Jiao, K., Chen, Z., Zhang, X., & Liu, Y. (2024). Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy. Science Advances, 10(37). https://doi.org/10.1126/sciadv.adi7764

Vancouver

Liu Y, Xu C, Zhang L, Xu G, Yang Z, Xiang L, et al. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy. Science Advances. 2024;10(37). doi:10.1126/sciadv.adi7764

BibTeX
@article{Liu2024,
  author = {Liu, Yun and Xu, Chen and Zhang, Li and Xu, Guiqin and Yang, Zhaojuan and Xiang, Lvzhu and Jiao, Kun and Chen, Zehong and Zhang, Xiaoren and Liu, Yongzhong},
  title = {Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {37},
  doi = {10.1126/sciadv.adi7764}
}
Kostenlos starten →